Schlagwortarchiv für: Publikationen: Prof. Dr. rer. nat. Volker Schirrmacher
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-03-17 / Int. J. Oncol. 2011 Jun;38(6):1719-29
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-03-17 / Int. J. Oncol. 2011 Jun;38(6):1719-292011-03-17 00:00:002021-11-15 16:59:03Targeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-12-18 / Vaccine 2011 Feb;29(6):1185-93
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-12-18 / Vaccine 2011 Feb;29(6):1185-932010-12-18 00:00:002021-11-15 16:59:23Antitumor vaccination by Newcastle Disease Virus Hemagglutinin-Neuraminidase plasmid DNA application: changes in tumor microenvironment and activation of innate anti-tumor immunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-12-01 / Int. J. Oncol. 2010 Dec;37(6):1439-52
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-12-01 / Int. J. Oncol. 2010 Dec;37(6):1439-522010-12-01 00:00:002021-11-15 16:59:47Transcriptome analysis and cytokine profiling of naive T cells stimulated by a tumor vaccine via CD3 and CD25
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-01 / Int. J. Oncol. 2010 Nov;37(5):1203-17
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-01 / Int. J. Oncol. 2010 Nov;37(5):1203-172010-11-01 00:00:002021-11-15 17:00:11Optimization studies for the coupling of bispecific antibodies to viral anchor molecules of a tumor vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-08-13 / Vaccine 2010 Oct;28(42):6891-900
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-08-13 / Vaccine 2010 Oct;28(42):6891-9002010-08-13 00:00:002021-11-15 17:00:34The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-09-01 / J BUON 2009 Sep;14 Suppl 1:S111-22
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-09-01 / J BUON 2009 Sep;14 Suppl 1:S111-222009-09-01 00:00:002021-11-15 17:00:58Polarization of human monocyte-derived dendritic cells to DC1 by in vitro stimulation with Newcastle Disease Virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-06-10 / J. Virol. 2009 Aug;83(16):8108-21
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-06-10 / J. Virol. 2009 Aug;83(16):8108-212009-06-10 00:00:002021-11-15 17:01:25Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-04-01 / Int. J. Oncol. 2009 Apr;34(4):971-82
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-04-01 / Int. J. Oncol. 2009 Apr;34(4):971-822009-04-01 00:00:002021-11-15 17:01:56Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-04-01 / Int. J. Oncol. 2009 Apr;34(4):951-62
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-04-01 / Int. J. Oncol. 2009 Apr;34(4):951-622009-04-01 00:00:002021-11-15 17:02:15Cross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-01-01 / Expert Rev Vaccines 2009 Jan;8(1):51-66
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-01-01 / Expert Rev Vaccines 2009 Jan;8(1):51-662009-01-01 00:00:002021-11-15 17:02:36Randomized clinical studies of anti-tumor vaccination: state of the art in 2008
